Warren E. Regelmann

An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.

Journal: Open forum infectious diseases

Published: August 12, 2025

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 29, 2019

Decreased Pseudomonas aeruginosa detection in children after separation of pediatric from adult cystic fibrosis clinics: A single center experience.

Journal: Pediatric pulmonology

Published: January 10, 2018

Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis.

Journal: Respiratory care

Published: April 21, 2017

Pulmonary function tests correlated with thoracic volumes in adolescent idiopathic scoliosis.

Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society

Published: January 14, 2016

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Journal: The Lancet. Respiratory medicine

Published: November 09, 2015

Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage.

Journal: Pediatrics

Published: February 26, 2015

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.

Journal: Pediatric pulmonology

Published: February 26, 2014

Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.

Journal: Annals of the American Thoracic Society

Published: October 03, 2013

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.

Journal: Pediatric diabetes

Published: November 24, 2012

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Journal: Pediatric pulmonology

Published: February 25, 2012

Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.

Journal: Pediatric pulmonology

Published: January 03, 2012

An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.

An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Decreased Pseudomonas aeruginosa detection in children after separation of pediatric from adult cystic fibrosis clinics: A single center experience.

Decreased Pseudomonas aeruginosa detection in children after separation of pediatric from adult cystic fibrosis clinics: A single center experience.

Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis.

Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis.

Pulmonary function tests correlated with thoracic volumes in adolescent idiopathic scoliosis.

Pulmonary function tests correlated with thoracic volumes in adolescent idiopathic scoliosis.

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage.

Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage.

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.

Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.

Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.

Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).